Cardiometabolic trajectories across midlife in parous women with polycystic ovary syndrome
American Journal of Epidemiology · 2025
DOI: 10.1093/aje/kwaf078 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Yingan Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Colorado School of Public Health, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIEHS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Compare cardiometabolic trajectories of 557 parous women with diagnosed, probable, and no polycystic ovary syndrome (PCOS) throughout 15-year follow-up (2002-2021). We defined PCOS status as: (1) clinically diagnosed; (2) probable: without diagnosis but ≥2 of the following: cycle length <21 or ≥35 days, free testosterone >75th percentile, or anti-Müllerian hormone >75th percentile; (3) no PCOS. Outcomes included longitudinal adiposity, blood pressure, lipids, glycemia, and adipokines. We used mixed-effects models to examine associations of PCOS status with the outcomes, adjusting for covariates. Women were 37 ± 5 years at baseline; 9.7% had diagnosed and 9.2% probable PCOS. Throughout follow-up, women with diagnosed versus no PCOS had higher adiposity, systolic blood pressure, triglycerides, hemoglobin A1c, fasting glucose, insulin, and leptin; and lower high-density lipoprotein and adiponectin. However, the diagnosed and probable PCOS groups had similar hemoglobin A1c (0.16 [95% CI, -0.20 to 0.52]), leptin (-4.20 [95% CI, -16.61 to 8.22] ng/mL), and adiponectin (0.99 [95% CI, -2.15 to 4.13] μg/mL). Both groups had less favorable profiles than women without PCOS, even after body mass index adjustment. Although women with diagnosed PCOS have the least favorable cardiometabolic profile throughout midlife, those with probable PCOS exhibited comparable glycemia and an altered adipokine pattern suggestive of adipocyte dysfunction independent of adiposity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Colorado School of Public Health, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado, Anschutz Medical Campus, Aurora, CO, United States.
- Division of Chronic Disease Research across the Lifecourse (CORaL), Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, United States.
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States.
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, United States.
- Diabetes Unit, Massachusetts General Hospital, Boston, MA, United States.
ORCID-Profile: Yingan Chen, Wei Perng
Förderung
- NICHD NIH HHS
- NIEHS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Chen, Y., Salmon, K., Rifas-Shiman, S. L., Fitz, V. W., Kazemi, M., Shifren, J., Hivert, M. F., Oken, E., Chavarro, J., & Perng, W. (2025). Cardiometabolic trajectories across midlife in parous women with polycystic ovary syndrome. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwaf078
Vancouver
Chen Y, Salmon K, Rifas-Shiman SL, Fitz VW, Kazemi M, Shifren J, et al. Cardiometabolic trajectories across midlife in parous women with polycystic ovary syndrome. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwaf078
BibTeX
@article{Chen2025,
author = {Chen, Yingan and Salmon, Kyle and Rifas-Shiman, Sheryl L and Fitz, Victoria W and Kazemi, Maryam and Shifren, Jan and Hivert, Marie-France and Oken, Emily and Chavarro, Jorge and Perng, Wei},
title = {Cardiometabolic trajectories across midlife in parous women with polycystic ovary syndrome},
journal = {American Journal of Epidemiology},
year = {2025},
doi = {10.1093/aje/kwaf078}
}
EUVIMED